Synovial sarcoma in children and adolescents: The European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 567-572

  Ferrari, Andrea ^a   de Salvo, G L ^b   Brennan, B ^c   van Noesel, M M ^d   De Paoli, A ^b   Casanova, M ^a   Francotte, N ^e   Kelsey, A ^c   Alaggio, R ^f   Oberlin, O ^g   Carli, M ^f   Ben Arush, M ^h   Bergeron, C ⁱ   Merks, J H M ^j   Jenney, M ^k   Stevens, M C ^l   Bisogno, G ^f   Orbach, D ^m  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e Department of Pediatrics   (Belgium)

^f UNIVERSITY OF PADOVA   (Italy)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h MEYER CHILDREN S HOSPITAL   (Israel)

ⁱ CENTRE LÉON BÉRARD   (France)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k CHILDREN S HOSPITAL FOR WALES   (United Kingdom)

^l UNIVERSITY OF BRISTOL   (United Kingdom)

^m INSTITUT CURIE   (France)

more..

Author keywords

Adolescents; Children; Clinical trial; Cooperative groups; Pediatric sarcoma; Synovial sarcoma

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; SURVIVAL RATE; SYNOVIAL SARCOMA; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL TRIAL; EUROPE; MULTICENTER STUDY; PROSPECTIVE STUDY; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS;

ADOLESCENT; CHILD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS;

EID: 84941633989     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu562     Document Type: Article

References (17)

1. Sultan I, Rodriguez-Galindo C, Saab R et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology and End Results Program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115: 3537-3547.
2. Kawai A, Woodruff J, Healey JH et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160.
3. Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003; 21: 1602-1611.
4. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101: 627-634.
5. Ferrari A, Bisogno G, Alaggio G et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008; 44: 1202-1209.
6. Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010; 55: 85-90.
7. Orbach D, Dowell HM, Rey A et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. Pediatr Blood Cancer 2011; 57(7): 1130-1136.
8. Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005; 5(2): 307-318.
9. Trassard M, Le Doussal V, Hacène K et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001; 19: 525-534.
10. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004; 22(20): 4040-4050.
11. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005; 16: 437-444.
12. Brecht IB, Ferrari A, Int-Veen C et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer 2006; 46(1): 11-17.
13. Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-362.
14. Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer 1988; 61: 209-220.
15. Canter RJ, Qin LX, Maki RG et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2007; 14(24): 8191-8197.
16. Italiano A, Penel N, Robin YM et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009; 20(3): 425-430.
17. Ferrari A, Miceli R, Rey A et al. Non-metastatic unresected pediatric nonrhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer 2011; 47: 724-731.